BLSM

Healthcare Biotechnology

BlossomHill Therapeutics, Inc.

$19.69

+1.10 +5.92% today

Price History

Not enough data

Key Stats

Market Cap

625.84M

Avg Volume

265,652

EPS

-$4.70

52W High

$27.99

52W Low

$15.25

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-4.98

P/B Ratio

-0.34

EV/EBITDA

-9.57

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Liquidity & Leverage

Current Ratio

5.42

Quick Ratio

5.12

Debt / Equity

0.28

Total Cash

95.38M

Total Debt

23.37M

About

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

bhtherapeutics.com